Table 2.
List of MS-based targeted proteomics validation studies of candidate PC protein markers.
| Potential Biomarker | Sample Cohort | Source | Method | Ref. |
|---|---|---|---|---|
| FASN, TPP1, SPON2 | 16 BPH, 57 PC | Tissue | PRM-MS analysis of 6 peptides corresponding to 3 target proteins | [75] |
| ADSV, TGM4, CD63, GLPK5, SPHMPSA, PAPP | 54 noncancer, 22 low-grade PC, 31 high-grade PC | EPS urinary EV | SRM-MS analysis of 64 peptides corresponding to 64 target proteins | [109] |
| C1QB, APOA4, CO9, ANT3, VTDB, PLMN, GPX3, ITIH4, CFAI, APOH, VTNC, IBP3, CLUS, APOA2, PEDF, TETN, CD14, LG3BP, CFAH, FCN3, HPT, CO3, APOA1, APOC3, SAMP, HEMO, CO6, KLK3/PSA, A2MG, A1At, APOE, A2Gl, TTHY, C1S, ZAG, AMBP, KNG1, CO4A, AACT, CAV1, TRFE | 86 time-point samples from 3 PC patients with BCR and 3 controls | Immunodepleted serum | SRM-MS analysis of 59 peptides corresponding to 41 target proteins | [84] |
| ITIH2, CD44, IGHG2, CDH13 | 25 aggressive PC, 25 non-aggressive PC | Serum | PRM-MS analysis of 41 N-glycosite-containing peptides corresponding to 37 target proteins | [110] |